

KERYX BIOPHARMACEUTICALS INC

Form 3

February 13, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Madison Greg

(Last)

(First)

(Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)

02/08/2014

3. Issuer Name and Ticker or Trading Symbol

KERYX BIOPHARMACEUTICALS INC [KERX]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner☒ Officer ☐ Other

(give title below) (specify below)

See Remarks

6. Individual or Joint/Group

Filing(Check Applicable Line)

☒ Form filed by One Reporting Person☐ Form filed by More than One Reporting PersonC/O KERYX
BIOPHARMACEUTICALS,
INC.,Â 750 LEXINGTON
AVENUE

(Street)

NEW YORK,Â NYÂ 10022

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned1. Title of Security
(Instr. 4)2. Amount of Securities Beneficially Owned
(Instr. 4)3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Common Stock

76,547 ⁽¹⁾ ⁽²⁾

D

Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)1. Title of Derivative Security
(Instr. 4)2. Date Exercisable and Expiration Date
(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

4. Conversion or Exercise

5. Ownership Form of

6. Nature of Indirect Beneficial Ownership

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3

			(Instr. 4)		Price of	Derivative	(Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Options (Right to Buy)	02/08/2015 ⁽³⁾	02/08/2024	Common Stock	80,000	\$ 15.21	D	Â
Stock Options (Right to Buy)	02/08/2014 ⁽⁴⁾	02/08/2024	Common Stock	115,000	\$ 15.21	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Madison Greg C/O KERYX BIOPHARMACEUTICALS, INC. 750 LEXINGTON AVENUE NEW YORK, NY 10022	Â	Â	Â See Remarks	Â

Signatures

/s/ Gregory P. Madison 02/13/2014

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of restricted stock vest as follows: 25,000 on February 8, 2014; 20,000 on February 8, 2015; and the remaining 40,000 in equal quarterly installments from February 8, 2015 through February 8, 2017.
- Shown net of the sale of 8,453 shares of common stock on February 10th, 2014 at a price of \$15.34 per share to satisfy Mr. Madison's income tax withholding obligation upon the vesting of 25,000 shares of restricted stock on February 8, 2014. Mr. Madison had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. Following the sale, Mr. Madison beneficially owns 76,547 shares of common stock of which 60,000 are restricted shares.
- (3) The options vest as follows: 26,667 on February 8, 2015; and the remaining 53,333 in equal quarterly installments from February 8, 2015 through February 8, 2017.
- The options will vest as follows: (i) 15,000 upon the first commercial sale of Zerenex(TM) (ferric citrate coordination complex) within 90 days of marketing approval by the FDA, (ii) 30,000 upon reported net sales for Zerenex of (greater than or equal to)\$25 million in a calendar quarter, (iii) 30,000 upon reported net sales for Zerenex of greater than or equal to \$50 million in a calendar quarter, and (iv) 40,000 upon reported net sales for Zerenex of greater than or equal to \$75 million in a calendar quarter.

Â

Remarks:

Executive Vice President and COO

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.